NEW DELHI, India — Gland Pharma shares climbed sharply on Tuesday, August 11, hitting a fresh 52-week high after the drugmaker reported a strong first-quarter performance for FY27. The stock rose as much as 12% in early trading, with investors assessing whether stronger US sales, improving profitability and new contract opportunities could ease some of the company’s earlier growth challenges.
According to NSE data, Gland Pharma shares reached an intraday high of ₹2,987, compared with the previous close of ₹2,667.30. The stock was trading near ₹2,977 during the session after the early surge.
Key Highlights
- Gland Pharma shares surged 12% to a fresh 52-week high of ₹2,987.
- Q1 FY27 consolidated net profit rose 47% year-on-year to ₹317 crore.
- US revenue jumped 32% to ₹981 crore, supporting overall growth.
- Management raised its constant-currency growth guidance to 15% from 12-13% earlier.
Gland Pharma Q1 FY27 results show stronger growth
Gland Pharma posted consolidated net profit after tax of ₹317 crore for the April-June quarter, up 47% from ₹215 crore in the corresponding period last year. Revenue from core operations increased 19.5% year-on-year to ₹1,800 crore from ₹1,506 crore.
The US market remained a major contributor to the quarterly improvement. Revenue from the region increased 32% year-on-year to ₹981 crore, while European revenue rose around 20% to ₹395 crore.
Profitability also strengthened during the quarter. EBITDA increased 33% year-on-year to ₹489 crore from ₹368 crore, while the EBITDA margin expanded to 27.16%, compared with 24.44% a year earlier.
CDMO business becomes a key growth driver
Gland Pharma’s contract development and manufacturing organisation (CDMO) business accounted for half of total revenue during the period and recorded 20% year-on-year growth.
The company has also entered into a CDMO partnership with a global pharmaceutical company. The deal has an estimated annualised revenue potential of approximately $90 million to $100 million once all products covered by the arrangement are commercialised.
The company launched four molecules in the US during the quarter, including multi-vitamin and leucovorin calcium. It also filed three ANDAs and received seven approvals during Q1 FY27.
Analysts see improving growth prospects
Jefferies said Gland Pharma’s first-quarter performance exceeded its earlier estimates, with the strong US business playing a central role. The brokerage also pointed to the company’s revised growth outlook, with management indicating 15% constant-currency growth for FY27 compared with its earlier 12-13% guidance.
“We believe many key challenges for Gland are behind it, with Cenexi breakeven, new contract wins & expansion into complex products,” said Jefferies analysts.
Goldman Sachs also highlighted potential upside from the company’s growth outlook, particularly if its RTU bag line receives approval in the third quarter of FY27.
“Q1 FY27 & reiterated confidence in at least 15% constant-currency growth for FY27, with potential upside if RTU bag line receives approval in Q3 FY27,” said Goldman Sachs analysts.
Margin risks and Cenexi remain key factors
Despite the stronger quarter, analysts identified risks that could affect the company’s trajectory. These include potential pressure on margins in the core business and the possibility of delays in Cenexi reaching pre-acquisition margins.
The latest results therefore point to improving operating momentum, but the sustainability of the growth outlook will depend on execution across new contracts, complex products and the company’s planned opportunities during FY27.
What is driving Gland Pharma’s stock rally?
The immediate trigger is the company’s strong Q1 FY27 performance, including higher profit, stronger US revenue, improved EBITDA margins and an upgraded 15% constant-currency growth outlook.
What could influence Gland Pharma’s growth ahead?
Analysts are watching the company’s CDMO opportunities, Cenexi’s progress, expansion into complex products and the expected RTU bag line approval in Q3 FY27. Margin pressure and potential delays at Cenexi remain identified risks.
Financial Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult a qualified financial adviser before making investment decisions.
Source Attribution: Information in this report is based solely on the supplied market report, including NSE data, company filings and analyst views from Jefferies and Goldman Sachs cited in the source material.
